{
    "2021-07-09": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year",
                "features": {
                    "keywords": [
                        "Mirikizumab",
                        "mucosal healing",
                        "ulcerative colitis",
                        "one year"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates",
                "features": {
                    "keywords": [
                        "GSK",
                        "Alector",
                        "MRK",
                        "AZN",
                        "FDA updates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study",
                "features": {
                    "keywords": [
                        "Mirikizumab",
                        "genes",
                        "mucosal healing",
                        "ulcerative colitis",
                        "phase 2 study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}